Tim Schlidt is the co-founder of psychedelic-focused VC fund Palo Santo. He is one of the leading voices pushing for the development of psychedelic-backed mental health therapies and has deployed over $25 million into 20 companies. Schlidt is also pushing for the FDA approval of psychedelic-assisted therapies to make them more accessible, affordable, and safe for patients suffering from treatment-resistant depression.
In this episode of Hone In, Saad sits down with him to talk about what goes down during a therapeutic trip, ongoing clinical trials, and the growing acceptance of psychedelics in mental health care.
This conversation is an absolute game-changer. It walks the tightrope between scientific inquiry and personal experiences, offering you a comprehensive understanding of the profound potential of therapeutic psychedelics.
WE DISCUSS:
How psychedelics can promote neuroplasticity
Anti-inflammatory and longevity benefits of psychedelics
MDMA and psilocybin (molly and mushrooms) for treatment-resistant depression
Tim's own experience with severe depression
The mental health benefits of “ego death”
IN THIS EPISODE YOU'LL LEARN:
The difference between a psychedelic microdose and a macrodose
Why psychedelics could yield better results than SSRIs
When to expect FDA approval of psychedelic therapies
How much psychedelic-assisted therapy costs
And more
Check out all the episodes at: : https://honehealth.com/edge/podcast/
Listen to the episodes on:
SPOTIFY: https://open.spotify.com/show/76Hg5OU5oOu7S9Ze6WPSlw
APPLE PODCASTS: https://podcasts.apple.com/us/podcast/hone-in/id1707026738
Watch clips from Hone In episodes on: YouTube: https://www.youtube.com/watch?v=JoOQaVPbgKQ
Get exclusive weekly tips from show guests in our newsletter:: https://hone-health.ck.page/hone-in
Follow us at:
HONE HEALTH INSTAGRAM: https://www.instagram.com/hone.health/?hl=en
SAAD ALAM INSTAGRAM: https://www.instagram.com/msaadalam/?hl=en
Learn More: https://honehealth.com/